Postischemic cardiac recovery in heme oxygenase-1 transgenic ischemic/reperfused mouse myocardium

B. Juhász, Balazs Varga, Attila Czompa, I. Bak, I. Lekli, R. Gesztelyi, Judit Zsuga, Adam Kemeny-Beke, M. Antal, Levente Szendrei, A. Tósaki

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Heme oxygenase-1 (HO-1) transgenic mice (Tg) were created using a rat HO-1 genomic transgene. Transgene expression was detected by RT-PCR and Western blots in the left ventricle (LV), right ventricle (RV) and septum (S) in mouse hearts, and its function was demonstrated by the elevated HO enzyme activity. Tg and non-transgenic (NTg) mouse hearts were isolated and subjected to ischemia/reperfusion. Significant post-ischemic recovery in coronary flow (CF), aortic flow (AF), aortic pressure (AOP) and first derivative of AOP (AOPdp/dt) were detected in the HO-1 Tg group compared to the NTg values. In HO-1 Tg hearts treated with 50 μmol/kg of tin protoporphyrin IX (SnPPIX), an HO enzyme inhibitor, abolished the post-ischemic cardiac recovery. HO-1 related carbon monoxide (CO) production was detected in NTg, HO-1 Tg and HO-1 Tg + SnPPIX treated groups, and a substantial increase in CO production was observed in the HO-1 Tg hearts subjected to ischemia/reperfusion. Moreover, in ischemia/reperfusion-induced tissue Na + and Ca 2+ gains were reduced in HO-1 Tg group in comparison with the NTg and HO-1 Tg + SnPPIX treated groups; furthermore K + loss was reduced in the HO-1 Tg group. The infarct size was markedly reduced from its NTg control value of 37 ± 4% to 20 ± 6% (P<0.05) in the HO-1 Tg group, and was increased to 47 ± 5% (P<0.05) in the HO-1 knockout (KO) hearts. Parallel to the infarct size reduction, the incidence of total and sustained ventricular fibrillation were also reduced from their NTg control values of 92% and 83% to 25% (P<0.05) and 8% (P<0.05) in the HO-1 Tg group, and were increased to 100% and 100% in HO-1 KO -/- hearts. Immunohistochemical staining of HO-1 was intensified in HO-1 Tg compared to the NTg myocardium. Thus, the HO-1 Tg mouse model suggests a valuable therapeutic approach in the treatment of ischemic myocardium.

Original languageEnglish
Pages (from-to)1973-1982
Number of pages10
JournalJournal of Cellular and Molecular Medicine
Volume15
Issue number9
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Heme Oxygenase-1
Myocardium
Reperfusion
Ischemia
Carbon Monoxide
Transgenes
Heart Ventricles
Arterial Pressure

Keywords

  • Heme oxygenase-1
  • Ischemia
  • Reperfusion

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

Postischemic cardiac recovery in heme oxygenase-1 transgenic ischemic/reperfused mouse myocardium. / Juhász, B.; Varga, Balazs; Czompa, Attila; Bak, I.; Lekli, I.; Gesztelyi, R.; Zsuga, Judit; Kemeny-Beke, Adam; Antal, M.; Szendrei, Levente; Tósaki, A.

In: Journal of Cellular and Molecular Medicine, Vol. 15, No. 9, 09.2011, p. 1973-1982.

Research output: Contribution to journalArticle

@article{e252f016a7054e47884c2b95ac76afb3,
title = "Postischemic cardiac recovery in heme oxygenase-1 transgenic ischemic/reperfused mouse myocardium",
abstract = "Heme oxygenase-1 (HO-1) transgenic mice (Tg) were created using a rat HO-1 genomic transgene. Transgene expression was detected by RT-PCR and Western blots in the left ventricle (LV), right ventricle (RV) and septum (S) in mouse hearts, and its function was demonstrated by the elevated HO enzyme activity. Tg and non-transgenic (NTg) mouse hearts were isolated and subjected to ischemia/reperfusion. Significant post-ischemic recovery in coronary flow (CF), aortic flow (AF), aortic pressure (AOP) and first derivative of AOP (AOPdp/dt) were detected in the HO-1 Tg group compared to the NTg values. In HO-1 Tg hearts treated with 50 μmol/kg of tin protoporphyrin IX (SnPPIX), an HO enzyme inhibitor, abolished the post-ischemic cardiac recovery. HO-1 related carbon monoxide (CO) production was detected in NTg, HO-1 Tg and HO-1 Tg + SnPPIX treated groups, and a substantial increase in CO production was observed in the HO-1 Tg hearts subjected to ischemia/reperfusion. Moreover, in ischemia/reperfusion-induced tissue Na + and Ca 2+ gains were reduced in HO-1 Tg group in comparison with the NTg and HO-1 Tg + SnPPIX treated groups; furthermore K + loss was reduced in the HO-1 Tg group. The infarct size was markedly reduced from its NTg control value of 37 ± 4{\%} to 20 ± 6{\%} (P<0.05) in the HO-1 Tg group, and was increased to 47 ± 5{\%} (P<0.05) in the HO-1 knockout (KO) hearts. Parallel to the infarct size reduction, the incidence of total and sustained ventricular fibrillation were also reduced from their NTg control values of 92{\%} and 83{\%} to 25{\%} (P<0.05) and 8{\%} (P<0.05) in the HO-1 Tg group, and were increased to 100{\%} and 100{\%} in HO-1 KO -/- hearts. Immunohistochemical staining of HO-1 was intensified in HO-1 Tg compared to the NTg myocardium. Thus, the HO-1 Tg mouse model suggests a valuable therapeutic approach in the treatment of ischemic myocardium.",
keywords = "Heme oxygenase-1, Ischemia, Reperfusion",
author = "B. Juh{\'a}sz and Balazs Varga and Attila Czompa and I. Bak and I. Lekli and R. Gesztelyi and Judit Zsuga and Adam Kemeny-Beke and M. Antal and Levente Szendrei and A. T{\'o}saki",
year = "2011",
month = "9",
doi = "10.1111/j.1582-4934.2010.01153.x",
language = "English",
volume = "15",
pages = "1973--1982",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Postischemic cardiac recovery in heme oxygenase-1 transgenic ischemic/reperfused mouse myocardium

AU - Juhász, B.

AU - Varga, Balazs

AU - Czompa, Attila

AU - Bak, I.

AU - Lekli, I.

AU - Gesztelyi, R.

AU - Zsuga, Judit

AU - Kemeny-Beke, Adam

AU - Antal, M.

AU - Szendrei, Levente

AU - Tósaki, A.

PY - 2011/9

Y1 - 2011/9

N2 - Heme oxygenase-1 (HO-1) transgenic mice (Tg) were created using a rat HO-1 genomic transgene. Transgene expression was detected by RT-PCR and Western blots in the left ventricle (LV), right ventricle (RV) and septum (S) in mouse hearts, and its function was demonstrated by the elevated HO enzyme activity. Tg and non-transgenic (NTg) mouse hearts were isolated and subjected to ischemia/reperfusion. Significant post-ischemic recovery in coronary flow (CF), aortic flow (AF), aortic pressure (AOP) and first derivative of AOP (AOPdp/dt) were detected in the HO-1 Tg group compared to the NTg values. In HO-1 Tg hearts treated with 50 μmol/kg of tin protoporphyrin IX (SnPPIX), an HO enzyme inhibitor, abolished the post-ischemic cardiac recovery. HO-1 related carbon monoxide (CO) production was detected in NTg, HO-1 Tg and HO-1 Tg + SnPPIX treated groups, and a substantial increase in CO production was observed in the HO-1 Tg hearts subjected to ischemia/reperfusion. Moreover, in ischemia/reperfusion-induced tissue Na + and Ca 2+ gains were reduced in HO-1 Tg group in comparison with the NTg and HO-1 Tg + SnPPIX treated groups; furthermore K + loss was reduced in the HO-1 Tg group. The infarct size was markedly reduced from its NTg control value of 37 ± 4% to 20 ± 6% (P<0.05) in the HO-1 Tg group, and was increased to 47 ± 5% (P<0.05) in the HO-1 knockout (KO) hearts. Parallel to the infarct size reduction, the incidence of total and sustained ventricular fibrillation were also reduced from their NTg control values of 92% and 83% to 25% (P<0.05) and 8% (P<0.05) in the HO-1 Tg group, and were increased to 100% and 100% in HO-1 KO -/- hearts. Immunohistochemical staining of HO-1 was intensified in HO-1 Tg compared to the NTg myocardium. Thus, the HO-1 Tg mouse model suggests a valuable therapeutic approach in the treatment of ischemic myocardium.

AB - Heme oxygenase-1 (HO-1) transgenic mice (Tg) were created using a rat HO-1 genomic transgene. Transgene expression was detected by RT-PCR and Western blots in the left ventricle (LV), right ventricle (RV) and septum (S) in mouse hearts, and its function was demonstrated by the elevated HO enzyme activity. Tg and non-transgenic (NTg) mouse hearts were isolated and subjected to ischemia/reperfusion. Significant post-ischemic recovery in coronary flow (CF), aortic flow (AF), aortic pressure (AOP) and first derivative of AOP (AOPdp/dt) were detected in the HO-1 Tg group compared to the NTg values. In HO-1 Tg hearts treated with 50 μmol/kg of tin protoporphyrin IX (SnPPIX), an HO enzyme inhibitor, abolished the post-ischemic cardiac recovery. HO-1 related carbon monoxide (CO) production was detected in NTg, HO-1 Tg and HO-1 Tg + SnPPIX treated groups, and a substantial increase in CO production was observed in the HO-1 Tg hearts subjected to ischemia/reperfusion. Moreover, in ischemia/reperfusion-induced tissue Na + and Ca 2+ gains were reduced in HO-1 Tg group in comparison with the NTg and HO-1 Tg + SnPPIX treated groups; furthermore K + loss was reduced in the HO-1 Tg group. The infarct size was markedly reduced from its NTg control value of 37 ± 4% to 20 ± 6% (P<0.05) in the HO-1 Tg group, and was increased to 47 ± 5% (P<0.05) in the HO-1 knockout (KO) hearts. Parallel to the infarct size reduction, the incidence of total and sustained ventricular fibrillation were also reduced from their NTg control values of 92% and 83% to 25% (P<0.05) and 8% (P<0.05) in the HO-1 Tg group, and were increased to 100% and 100% in HO-1 KO -/- hearts. Immunohistochemical staining of HO-1 was intensified in HO-1 Tg compared to the NTg myocardium. Thus, the HO-1 Tg mouse model suggests a valuable therapeutic approach in the treatment of ischemic myocardium.

KW - Heme oxygenase-1

KW - Ischemia

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=80052184600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052184600&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2010.01153.x

DO - 10.1111/j.1582-4934.2010.01153.x

M3 - Article

C2 - 20716121

AN - SCOPUS:80052184600

VL - 15

SP - 1973

EP - 1982

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 9

ER -